Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

Summary

This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients with sarcomatoid mesothelioma than giving immunotherapy alone.

Timeline

Start

2024-11-27

Primary completion

2026-12-15

Completion

2026-12-15

Drugs

Indications